Author: n Beth Molen

Shock and dismay have already begun as Americans face next year’s health insurance costs—and it looks like everyone will be in for some grim numbers.

So far, much of the attention has been on the stratospheric prices that Americans might see on plans they buy from Affordable Care Act marketplaces. Critical tax credits for those plans are set to expire at the end of the year, and, on top of that, insurers have proposed a median 18 percent price increase for 2026. With the higher prices and a loss of credits, some Americans could see their monthly premiums more than double.

In an analysis last month, nonpartisan health policy group KFF estimated that, on average, ACA marketplace premiums would rise 114 percent, going from $888 in 2025 to $1,904 in 2026.

Read full article

Comments

Amid the chaos of the Trump administration’s haphazard job cuts and a mass exodus of leadership, the Food and Drug Administration is experiencing a slowdown of drug reviews and approvals, according to an analysis reported by Stat News.

An assessment of metrics by RBC Capital Markets analysts found that FDA drug approvals dropped 14 percentage points in the third quarter compared to the average of the six previous quarters—falling from an average of 87 percent to 73 percent this past quarter. In line with that finding, analysts noted that the delay rate in meeting deadlines for drug application reviews rose from an average of 4 percent to 11 percent.

The FDA also rejected more applications than normal, going from a historical average of 10 percent to 15 percent in the third quarter. A growing number of rejections relate to problems at manufacturing plants, which in turn could suggest problems with the FDA’s inspection and auditing processes.

Read full article

Comments

For some cases of bacterial vaginosis, treatment should include a package deal, doctors now say.

The American College of Obstetricians & Gynecologists (ACOG) updated its clinical guidance Friday to fit with recent data indicating that treatment for recurring bacterial vaginosis (BV) in women is significantly more effective if their male partners are also treated at the same time—with both an oral antibiotic and an antibiotic cream directly onto the potentially offending member.

“Partner therapy offers us another avenue for hopefully preventing recurrence and helping people feel better faster,” Christopher Zahn, chief of clinical practice and health equity and quality at ACOG, said in a statement.

Read full article

Comments